Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Rev Clin Esp (Barc) ; 217(9): 522-525, 2017 Dec.
Article in English, Spanish | MEDLINE | ID: mdl-29032960

ABSTRACT

OBJECTIVES: To ascertain the correlation between the partial pressure of oxygen (PaO2) and oxyhaemoglobin saturation by pulse oximetry (SpO2) in patients who were admitted to the emergency department with suspected acute respiratory failure. MATERIAL AND METHODS: A prospective, observational multicentre study was conducted in the emergency departments of 3 Spanish hospitals. RESULTS: The study included 166 patients who presented mean±standard deviation PaO2, SpO2 and fraction of inspired oxygen (FiO2) values of 61.64±17.3mmHg, 87.61±8.8% and 0.28±0.15%, respectively. The median PaO2/FiO2 and SpO2/FiO2 ratios were 256.6 and 359.2, respectively. The correlation between PaO2/FiO2 and the SpO2/FiO2 was 0.745 (P<.001). CONCLUSIONS: The SpO2/FiO2 ratio can be used to calculate PaO2/FiO2 and determine the oxygenation state of patients with acute respiratory failure.

2.
Article in English | MEDLINE | ID: mdl-28559274

ABSTRACT

We explored if baseline CD4/CD8 T-cell ratio is associated with immunodiscordant response to antiretroviral therapy in HIV-infected subjects. Comparing immunodiscordant and immunoconcordant subjects matched by pretreatment CD4 counts, we observed a lower pretreatment CD4/CD8 T-cell ratio in immunodiscordant subjects. Furthermore, pretreatment CD4/CD8 T-cell ratio, but not CD4 counts, correlated with the main immunological alterations observed in immunodiscordants, including increased regulatory T-cell (Treg) frequency and T-cell turnover-related markers. Then, in a larger cohort, only baseline CD4/CD8 T-cell ratio was independently associated with immunodiscordance, after adjusting by the viral CXCR4-tropic HIV variants. Our results suggest that the CD4/CD8 T-cell ratio could be an accurate biomarker of the subjacent immunological damage triggering immunodiscordance.


Subject(s)
Antiretroviral Therapy, Highly Active/methods , CD4-CD8 Ratio , CD8-Positive T-Lymphocytes/immunology , HIV Infections/drug therapy , HIV Infections/immunology , T-Lymphocytes, Regulatory/immunology , Adult , Anti-HIV Agents/therapeutic use , Biomarkers/metabolism , Cell Survival/drug effects , Didanosine/therapeutic use , Female , Humans , Male , Middle Aged , Receptors, CXCR4/immunology , Stavudine/therapeutic use , Viral Load , Zalcitabine/therapeutic use , Zidovudine/therapeutic use
3.
Antiviral Res ; 117: 69-74, 2015 May.
Article in English | MEDLINE | ID: mdl-25766861

ABSTRACT

The aim was to analyze clinical complications in HIV-infected subjects who persistently maintain low CD4 levels despite virological response to cART in the Spanish CoRIS cohort. The main inclusion criteria were CD4 counts <200cells/mm(3) at cART-initiation and at least 2years under cART achieving a viral load <500copies/mL. Those patients with CD4 counts <250cells/mm(3) 2years after cART were classified as the Low-CD4 group, and clinical events were collected from this time-point. Poisson regression models were used to calculate incidence rate ratios of death, AIDS-defining events, serious non-AIDS-defining events (NAE) and of each specific NAE category (non-AIDS-defining malignancies (non-ADM), cardiovascular, kidney- and liver-related events). Of 9667 patients in the cohort, a total of 1128 met the criteria and 287 (25.4%) were classified in the Low-CD4 group. A higher risk of death (aIRR: 4.71; 95% CI: 1.88-11.82; p-value=0.001) and of non-ADM were observed in this group (aIRR: 2.23; 95% CI: 1.07-4.63; p=0.03). Our results stress the need to control accelerated aging in this population to counter their increased risk of non-AIDS-defining diseases, particularly cancer, and are consistent with the concept that clinical complications are potentially affected by genetics and lifestyle.


Subject(s)
Antiretroviral Therapy, Highly Active , HIV Infections/complications , HIV Infections/immunology , Adult , Aged , CD4 Lymphocyte Count , Cardiovascular Diseases/complications , Cardiovascular Diseases/epidemiology , Cohort Studies , Female , HIV Infections/drug therapy , HIV Infections/virology , Humans , Male , Middle Aged , Neoplasms/complications , Neoplasms/epidemiology , Prospective Studies , Regression Analysis , Risk Factors , Spain/epidemiology , Time Factors , Viral Load , Young Adult
4.
Radiologia ; 48(2): 99-102, 2006.
Article in Spanish | MEDLINE | ID: mdl-17058375

ABSTRACT

Amiodarone is a triiodinated antiarrhythmic drug that accumulates in alveolar macrophages. Its use is limited by its high rate of associated pulmonary toxicity, estimated at 5-7%. Radiologic findings for pulmonary toxicity caused by amiodarone are unspecific and varied. The most common finding is subpleural reticular-type interstitial thickening, predominately in the bases of the lungs. However, the presence of parenchymal nodules is an uncommon presentation. We report the case of a woman treated with amiodarone that presented multiple nodular lesions at plain-film radiography and high-resolution CT that were compatible with pulmonary toxicity caused by amiodarone at pathologic examination.


Subject(s)
Amiodarone/adverse effects , Anti-Arrhythmia Agents/adverse effects , Lung Diseases/chemically induced , Lung Diseases/diagnostic imaging , Pulmonary Alveoli/diagnostic imaging , Tomography, X-Ray Computed , Aged , Female , Humans
5.
Radiología (Madr., Ed. impr.) ; 48(2): 99-102, mar. 2006. ilus
Article in Es | IBECS | ID: ibc-044148

ABSTRACT

La amiodarona es un antiarrítmico triyodado que se deposita en los macrófagos alveolares, cuyo uso se ve limitado por su toxicidad pulmonar que presenta una incidencia estimada del 5-7%. Los hallazgos radiológicos de la toxicidad pulmonar por amiodarona son inespecíficos y variados, siendo el más frecuente un engrosamiento intersticial de tipo reticular subpleural de predominio en bases. La presencia de nódulos parenquimatosos es, sin embrago, una forma infrecuente de presentación de esta entidad. Exponemos el caso de una mujer en tratamiento con amiodarona que presentaba en la radiología simple de tórax y tomografía computarizada (TC) de alta resolución múltiples lesiones nodulares cuyo posterior estudio anatomopatológico confirmaba su compatibilidad con toxicidad pulmonar por amiodarona


Amiodarone is a triiodinated antiarrhythmic drug that accumulates in alveolar macrophages. Its use is limited by its high rate of associated pulmonary toxicity, estimated at 5-7%. Radiologic findings for pulmonary toxicity caused by amiodarone are unspecific and varied. The most common finding is subpleural reticular-type interstitial thickening, predominately in the bases of the lungs. However, the presence of parenchymal nodules is an uncommon presentation. We report the case of a woman treated with amiodarone that presented multiple nodular lesions at plain-film radiography and high-resolution CT that were compatible with pulmonary toxicity caused by amiodarone at pathologic examination


Subject(s)
Female , Aged , Humans , Anti-Arrhythmia Agents/toxicity , Amiodarone/toxicity , Lung Diseases/chemically induced , Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/drug therapy , Amiodarone/therapeutic use , Biopsy, Fine-Needle , Lung Diseases/pathology
6.
Rev Clin Esp ; 203(5): 230-5, 2003 May.
Article in Spanish | MEDLINE | ID: mdl-12765569

ABSTRACT

BACKGROUND: The incidence of embolism in atrial flutter has been underestimated in the routine clinical practice. PATIENTS AND METHODS: In this study the incidence of thromboembolic events after restoration of sinus rhythm (by catheter ablation or cardioversion) was compared in two groups of consecutive patients, with a different anticoagulation protocol. A total of 169 patients were evaluated. A first retrospective analysis of 79 non anticoagulated patients (group I). A second prospective group of 90 patients who were treated with an anticoagulation protocol (group II) similar to that for patients with atrial fibrillation. All had typical atrial flutter of at least one month's duration before the procedure. RESULTS: The mean age of patients in group I was 61 12 years and the mean left ventricular ejection fraction was 57 6%. Patients in group II had a mean age of 61 10 years and the mean left ventricular ejection fraction was 56 9%. No differences were observed regarding prevalence of structural cardiopathy, arterial hypertension, diabetes mellitus, left ventricular dysfunction, atrial size or atrial fibrillation between the two groups of patients. Four patients in the retrospective analysis (5%) had an embolic event associated with the procedure, compared with 0 (0%) in the group of patients treated with the anticoagulation protocol. The efficient anticoagulation was associated with a lower risk of thromboembolic events (p < 0.05). CONCLUSIONS: The incidence of embolic events after reversion to sinusal rhythm of persistent atrial flutter can be decreased. These patients should follow the same recommendations of anticoagulation that apply for patients with persistent atrial fibrillation that are going to be reverted to sinus rhythm.


Subject(s)
Atrial Flutter/complications , Electric Countershock/instrumentation , Sick Sinus Syndrome/complications , Sick Sinus Syndrome/therapy , Thromboembolism/etiology , Anticoagulants/therapeutic use , Electrocardiography , Female , Humans , Male , Middle Aged , Prospective Studies , Retrospective Studies , Sick Sinus Syndrome/diagnosis , Thromboembolism/drug therapy
7.
Rev. clín. esp. (Ed. impr.) ; 203(5): 230-235, mayo 2003.
Article in Es | IBECS | ID: ibc-21729

ABSTRACT

Pacientes y métodos. En este estudio se compara la incidencia de eventos tromboembólicos después de restaurar el ritmo sinusal (por ablación con catéter o cardioversión) en dos grupos consecutivos de pacientes con un protocolo de anticoagulación diferente. Se evaluaron 169 pacientes. Un primer análisis retrospectivo de 79 pacientes no anticoagulados (grupo I). Un segundo grupo prospectivo de 90 pacientes se trató con un protocolo de anticoagulación (grupo II) similar al de los pacientes con fibrilación auricular. Todos presentaban aleteo auricular típico de al menos un mes de duración antes del procedimiento. Resultados. Grupo I: la edad media fue 61ñ12 años y la fracción de eyección ventricular izquierda media de 57 ñ 6 por ciento. Grupo II: tuvo una edad media 61 ñ 10 años y fracción de eyección ventricular izquierda media de 56 ñ 9 por ciento. No hubo ninguna diferencia en la prevalencia de cardiopatía estructural, hipertensión arterial, diabetes mellitus, disfunción ventricular izquierda, tamaño auricular o fibrilación auricular entre los dos grupos de pacientes. Cuatro pacientes del análisis retrospectivo (5 por ciento) presentaron un episodio embólico asociado con el procedimiento, comparado con 0 (0 por ciento) de los pacientes tratados con un protocolo de anticoagulación. La anticoagulación eficaz se asoció con un menor riesgo de tromboembolismo (p < 0,05). Conclusiones. Es posible reducir la incidencia de eventos embólicos después de la reversión a ritmo sinusal del aleteo auricular persistente. Estos pacientes deben seguir las mismas recomendaciones de anticoagulación que los pacientes con fibrilación auricular persistente que van a ser revertidos a ritmo sinusal (AU)


Subject(s)
Middle Aged , Male , Female , Humans , Sick Sinus Syndrome , Thromboembolism , Retrospective Studies , Prospective Studies , Atrial Flutter , Anticoagulants , Electrocardiography , Electric Countershock
SELECTION OF CITATIONS
SEARCH DETAIL
...